News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co. (MRK) To Present Data From APPROVe Trial At American College of Rheumatology Annual Scientific Meeting In San Antonio On Oct. 18


10/19/2005 5:11:49 PM

Merck & Co., Inc. today announced that it will present data from its APPROVe (Adenomatous Polyp Prevention on VIOXX) clinical trial at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Antonio on Oct. 18. The company announced a voluntary worldwide withdrawal of VIOXX(R) (rofecoxib), its arthritis and acute pain medication from the marketplace worldwide on Sept. 30, based on new, three-year data from the trial.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES